中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Issue 7
Jul.  2014
Turn off MathJax
Article Contents

Controversial problems in management of cirrhotic ascites

DOI: 10.3969/j.issn.1001-5256.2014.07.006
  • Received Date: 2014-03-31
  • Published Date: 2014-07-20
  • Ascites is an important indicator of poor prognosis of liver cirrhosis. Although several guidelines and consensus statements on the management of ascites have been published in the past years, there are still a lot of controversial problems in this regard. The current controversial problems and difficulties in the management of ascites, such as the timing of sodium supplementation or sodium restriction, the selection of diuretics, the application value of aquaretics, the strategy of albumin administration after large- volume paracentesis, and the indications and efficacy of transjugular intrahepatic portosystemic shunt, are reviewed. It is pointed out that further studies on these problems with evidence- based medicine means will enhance the diagnosis and treatment of cirrhotic ascites and improve patients' prognosis.

     

  • loading
  • [1]European Association for the Study of the Liver.EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis[J].J Hepatol, 2010, 53 (3) :397-417.
    [2]RUNYON BA, AASLD.Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012[J].Hepatology, 2013, 57 (4) :1651-1653.
    [3]MOORE KP, WONG F, GINES P, et al.The management of ascites in cirrhosis:report on the consensus conference of the International Ascites Club[J].Hepatology, 2003, 38 (1) :258-266.
    [4]REYNOLDS TB, LIEBERMAN FL, GOODMAN AR.Advantages of treatment of ascites without sodium restriction and without complete removal of excess fluid[J].Gut, 1978, 19 (6) :549-553.
    [5]GAUTHIER A, LEVY VG, QUINTON A, et al.Salt or no salt in the treatment of cirrhotic ascites:a randomised study[J].Gut, 1986, 27 (6) :705-709.
    [6]GUEVARA M, CARDENAS A, URIZ J, et al.Prognosis in patients with cirrhosis and ascites[M]//GINS P, ARROYO V, RODS J, et al.Ascites and renal dysfunction in liver disease:pathogenesis, diagnosis and treatment.Malden:BlackwellPublishers, 2005:260-270.
    [7]SERSTT, GUSTOT T, RAUTOU PE, et al.Severe hyponatremia is a better predictor of mortality than MELDNa in patients with cirrhosis and refractory ascites[J].J Hepatol, 2012, 57 (2) :274-280.
    [8]SANTOS J, PLANAS R, PARDO A, et al.Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis.A randomized comparative study of efficacy and safety[J].J Hepatol, 2003, 39 (2) :187-192.
    [9]ANGELI P, FASOLATO S, MAZZA E, et al.Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis:results of an open randomised clinical trial[J].Gut, 2010, 59 (1) :98-104.
    [10]BERNARDI M.Optimum use of diuretics in managing ascites in patients with cirrhosis[J].Gut, 2010, 59 (1) :10-11.
    [11]WONG F, WATSON H, GERBES A, et al.Satavaptan for the management of ascites in cirrhosis:efficacy and safety across the spectrum of ascites severity[J].Gut, 2012, 61 (1) :108-116.
    [12]DAHL E, GLUUD LL, KIMER N, et al.Meta-analysis:the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia[J].Aliment Pharmacol Ther, 2012, 36 (7) :619-626.
    [13]TORRES VE, CHAPMAN AB, DEVUYST O, et al.Tolvaptan in patients with autosomal dominant polycystic kidney disease[J].N Engl J Med, 2012, 367 (25) :2407-2418.
    [14]GINES A, FERNANDEZ-ESPARRACH G, MONESCILLO A, et al.Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis[J].Gastroenterology, 1996, 111 (4) :1002-1110.
    [15]POZZI M, OSCULATI G, BOARI G, et al.Time course of circulatory and humoral effects of rapid total paracentesis in cirrhotic patients with tense, refractory ascites[J].Gastroenterology, 1994, 106 (3) :709-719.
    [16]CAMPBELL MS, BRENSINGER CM, SANYAL AJ, et al.Quality of life in refractory ascites:transjugular intrahepatic portal-systemic shunting versus medical therapy[J].Hepatology, 2005, 42 (3) :635-640.
    [17]SALERNO F, CAMMA C, ENEA M, et al.Transjugular intrahepatic portosystemic shunt for refractory ascites:a meta-analysis of individual patient data[J].Gastroenterology, 2007, 133 (3) :825-834.
    [18]MALINCHOC M, KAMATH PS, GORDON FD, et al.A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts[J].Hepatology, 2000, 31 (4) :864-871.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (2761) PDF downloads(813) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return